LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 14

Search options

  1. Article ; Online: Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.

    Squizzato, Alessandro / Keller, Tymen / Romualdi, Erica / Middeldorp, Saskia

    The Cochrane database of systematic reviews

    2011  , Issue 1, Page(s) CD005158

    Abstract: Background: Aspirin is the prophylactic antiplatelet drug of choice for people with cardiovascular disease. Adding a second antiplatelet drug to aspirin may produce additional benefit for those at high risk and those with established cardiovascular ... ...

    Abstract Background: Aspirin is the prophylactic antiplatelet drug of choice for people with cardiovascular disease. Adding a second antiplatelet drug to aspirin may produce additional benefit for those at high risk and those with established cardiovascular disease.
    Objectives: To quantify the benefit and harm of adding clopidogrel to standard long-term aspirin therapy for preventing cardiovascular events in people at high risk of cardiovascular disease and those with established cardiovascular disease.
    Search strategy: The searches have been updated: CENTRAL (Issue 3 2009), MEDLINE (2002 to September 2009) and EMBASE (2002 to September 2009).
    Selection criteria: All randomized controlled trials comparing long term use of aspirin plus clopidogrel with aspirin plus placebo or aspirin alone in patients with coronary disease, ischemic cerebrovascular disease, peripheral arterial disease, or at high risk of atherothrombotic disease were included.
    Data collection and analysis: Data on mortality, non-fatal myocardial infarction, non-fatal stroke, unstable angina, heart failure, revascularizations, major and minor bleeding, and all adverse events were collected. The overall treatment effect was estimated by the pooled odds ratio (OR) with 95% confidence interval (CI) using a fixed-effect model (Mantel-Haenszel).
    Main results: No new studies were identified from the updated searches. A total of two RCTs were found: the CHARISMA and the CURE study. The CURE study enrolled only patients with a recent non-ST segment elevation acute coronary syndrome. The use of clopidogrel plus aspirin, compared with placebo plus aspirin, was associated with a lower risk of cardiovascular events (OR: 0.87, 95% CI 0.81 to 0.94; P<0.01) and a higher risk of major bleeding (OR 1.34, 95% CI 1.14 to 1.57; P<0.01). Overall, we would expect 13 cardiovascular events to be prevented for every 1000 patients treated with the combination, but 6 major bleeds would be caused. In the CURE trial, for every 1000 people treated, 23 events would be avoided and 10 major bleeds would be caused. In the CHARISMA trial, for every 1000 people treated, 5 cardiovascular events would be avoided and 3 major bleeds would be caused.
    Authors' conclusions: The available evidence demonstrates that the use of clopidogrel plus aspirin is associated with a reduction in the risk of cardiovascular events and an increased risk of bleeding compared with aspirin alone. Only in patients with acute non-ST coronary syndrome benefits outweigh harms.
    MeSH term(s) Aspirin/adverse effects ; Aspirin/therapeutic use ; Cardiovascular Diseases/prevention & control ; Clopidogrel ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Humans ; Platelet Aggregation Inhibitors/adverse effects ; Platelet Aggregation Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Ticlopidine/adverse effects ; Ticlopidine/analogs & derivatives ; Ticlopidine/therapeutic use
    Chemical Substances Platelet Aggregation Inhibitors ; Clopidogrel (A74586SNO7) ; Ticlopidine (OM90ZUW7M1) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2011-01-19
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Review ; Systematic Review
    ISSN 1469-493X
    ISSN (online) 1469-493X
    DOI 10.1002/14651858.CD005158.pub3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Influenza vaccines for preventing coronary heart disease.

    Keller, Tymen / Weeda, Viola B / van Dongen, Carlo J / Levi, Marcel

    The Cochrane database of systematic reviews

    2008  , Issue 3, Page(s) CD005050

    Abstract: Background: Vaccination against influenza may reduce the risk of coronary heart disease. However the evidence is scarce and the size of the benefit is unknown.: Objectives: To assess the potential benefit of influenza vaccination for primary and ... ...

    Abstract Background: Vaccination against influenza may reduce the risk of coronary heart disease. However the evidence is scarce and the size of the benefit is unknown.
    Objectives: To assess the potential benefit of influenza vaccination for primary and secondary prevention of coronary heart disease.
    Search strategy: We searched the Cochrane Central Register of Controlled Trials, Issue 4 2007, MEDLINE (2005 to January 2008) and EMBASE (2005 to January 2008). Furthermore, we searched databases for recent or ongoing trials and reference lists of articles. Lastly, we contacted pharmaceutical companies for non published data or trials on influenza vaccination. No language restrictions were applied.
    Selection criteria: Randomised clinical trials of influenza vaccination compared to placebo or no treatment in primary or secondary prevention with outcome on coronary heart disease.
    Data collection and analysis: Data extraction and the assessment of quality was done with a predefined form by two review authors independently. We contacted investigators when data on the outcome were missing.
    Main results: In the two included trials, 778 participants were randomised to vaccination or placebo. Only 39 participants died a cardiovascular death. In addition, only 35 participants had an acute myocardial infarction. Consequently, estimates of treatment effects were imprecise.
    Authors' conclusions: Despite the significant effect noted in the studies, we concluded that there are not enough data to evaluate the effect of vaccination on coronary heart disease.
    MeSH term(s) Coronary Disease/mortality ; Coronary Disease/prevention & control ; Humans ; Influenza Vaccines/therapeutic use ; Randomized Controlled Trials as Topic
    Chemical Substances Influenza Vaccines
    Language English
    Publishing date 2008-07-16
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Review ; Systematic Review
    ISSN 1469-493X
    ISSN (online) 1469-493X
    DOI 10.1002/14651858.CD005050.pub2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Infection and inflammation and the coagulation system.

    Levi, Marcel / Keller, Tymen T / van Gorp, Eric / ten Cate, Hugo

    Cardiovascular research

    2003  Volume 60, Issue 1, Page(s) 26–39

    Abstract: Severe infection and inflammation almost invariably lead to hemostatic abnormalities, ranging from insignificant laboratory changes to severe disseminated intravascular coagulation (DIC). Systemic inflammation results in activation of coagulation, due to ...

    Abstract Severe infection and inflammation almost invariably lead to hemostatic abnormalities, ranging from insignificant laboratory changes to severe disseminated intravascular coagulation (DIC). Systemic inflammation results in activation of coagulation, due to tissue factor-mediated thrombin generation, downregulation of physiological anticoagulant mechanisms, and inhibition of fibrinolysis. Pro-inflammatory cytokines play a central role in the differential effects on the coagulation and fibrinolysis pathways. Vice-versa, activation of the coagulation system may importantly affect inflammatory responses by direct and indirect mechanisms. Apart from the general coagulation response to inflammation associated with severe infection, specific infections may cause distinct features, such as hemorrhagic fever or thrombotic microangiopathy. The relevance of the cross-talk between inflammation and coagulation is underlined by the promising results in the treatment of severe systemic infection with modulators of coagulation and inflammation.
    MeSH term(s) Antithrombins/therapeutic use ; Blood Coagulation/immunology ; Cytokines/immunology ; Disseminated Intravascular Coagulation/blood ; Disseminated Intravascular Coagulation/drug therapy ; Disseminated Intravascular Coagulation/immunology ; Endothelium, Vascular/immunology ; Fibrinolysis ; Hemostasis ; Humans ; Inflammation/blood ; Lipoproteins/therapeutic use ; Protein C/therapeutic use ; Sepsis/blood
    Chemical Substances Antithrombins ; Cytokines ; Lipoproteins ; Protein C ; lipoprotein-associated coagulation inhibitor
    Language English
    Publishing date 2003-07-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80340-6
    ISSN 1755-3245 ; 0008-6363
    ISSN (online) 1755-3245
    ISSN 0008-6363
    DOI 10.1016/s0008-6363(02)00857-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Influenza infection and risk of acute pulmonary embolism

    Zaaijer Hans L / Gerdes Victor EA / Ronkes Brechje / Keller Tymen T / van Wissen Matthijs / van Gorp Eric CM / Brandjes Dees PM / Levi Marcel / Büller Harry R

    Thrombosis Journal, Vol 5, Iss 1, p

    2007  Volume 16

    Abstract: Abstract Background Influenza infections have been associated with procoagulant changes. Whether influenza infections lead to an increased risk of pulmonary embolism remains to be established. Methods We conducted a nested case control study in a large ... ...

    Abstract Abstract Background Influenza infections have been associated with procoagulant changes. Whether influenza infections lead to an increased risk of pulmonary embolism remains to be established. Methods We conducted a nested case control study in a large cohort of patients with a clinical suspicion of having pulmonary embolism. Blood samples were collected to investigate the presence of influenza A and B by complement fixation assay (CFA). We compared case patients, in whom pulmonary embolism was proven (n = 102), to controls, in whom pulmonary embolism was excluded (n = 395). Furthermore, we compared symptoms of influenza-like illness in both patient groups 2 weeks prior to inclusion in the study, using the influenza-like illness (ILI) score, which is based on a questionnaire. We calculated the risk of pulmonary embolism associated with influenza infection. Results The percentage of patients with influenza A was higher in the control group compared to the case group (4.3% versus 1.0%, respectively, odds ratio 0.22; 95% CI: 0.03–1.72). Influenza B was not detectable in any of the cases and was found in 3 of the 395 controls (0.8%). The ILI score was positive in 24% of the cases and 25% in the control persons (odds ratio 1.16, 95% CI: 0.67–2.01). We did not observe an association between the ILI score and proven influenza infection. Conclusion In this clinical study, influenza infection was not associated with an increased risk of acute pulmonary embolism. The ILI score is non-specific in this clinical setting.
    Keywords Diseases of the circulatory (Cardiovascular) system ; RC666-701 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Cardiovascular ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
    Subject code 610 ; 616
    Language English
    Publishing date 2007-10-01T00:00:00Z
    Publisher BioMed Central
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: In vivo effects of C-reactive protein (CRP)-infusion into humans.

    Bisoendial, Radjesh / Birjmohun, Rakesh / Keller, Tymen / van Leuven, Sander / Levels, Han / Levi, Marcel / Kastelein, John / Stroes, Erik

    Circulation research

    2005  Volume 97, Issue 12, Page(s) e115–6

    MeSH term(s) C-Reactive Protein/toxicity ; Drug Contamination ; Endotoxins/toxicity ; Humans ; Inflammation/chemically induced ; Recombinant Proteins/toxicity
    Chemical Substances Endotoxins ; Recombinant Proteins ; C-Reactive Protein (9007-41-4)
    Language English
    Publishing date 2005-12-09
    Publishing country United States
    Document type Comment ; Letter
    ZDB-ID 80100-8
    ISSN 1524-4571 ; 0009-7330 ; 0931-6876
    ISSN (online) 1524-4571
    ISSN 0009-7330 ; 0931-6876
    DOI 10.1161/01.RES.0000196746.75724.8b
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research.

    de Kruif, Martijn D / van Gorp, Eric C M / Keller, Tymen T / Ossewaarde, Jacobus M / ten Cate, Hugo

    Cardiovascular research

    2005  Volume 65, Issue 2, Page(s) 317–327

    Abstract: Mouse models have been frequently used in the study of Chlamydia pneumoniae (also known as Chlamydophila pneumoniae) infections. This gram-negative obligate intracellular bacterium causes respiratory infections, followed by dissemination of the bacterium ...

    Abstract Mouse models have been frequently used in the study of Chlamydia pneumoniae (also known as Chlamydophila pneumoniae) infections. This gram-negative obligate intracellular bacterium causes respiratory infections, followed by dissemination of the bacterium to various organs throughout the body, including cardiovascular tissues, supporting the current hypothesis of a relationship between C. pneumoniae and atherosclerosis. Recently, clinical trials evaluated the effect of antichlamydial antibiotics on secondary cardiovascular events. Although small studies showed some effect, the large WIZARD study did not confirm these results, and the role of antichlamydial antibiotics in prevention of secondary events was questioned. To address these issues, data obtained from mouse models were systematically reviewed here. C. pneumoniae infections showed atherogenic properties in mice that were reproducible and confirmed by different research groups. However, antibiotic therapy was of limited value in these mouse models. Antibiotic therapy effectively cleared the acute infection, but did not influence the atherogenic properties of C. pneumoniae unless the therapy was started early during the acute infection. The results summarized here may help to better understand the results of the clinical antibiotic trials.
    MeSH term(s) Acute Disease ; Animals ; Anti-Bacterial Agents/therapeutic use ; Arteriosclerosis/immunology ; Arteriosclerosis/microbiology ; Arteriosclerosis/prevention & control ; Chlamydophila Infections/drug therapy ; Chlamydophila Infections/immunology ; Chlamydophila pneumoniae ; Mice ; Mice, Inbred Strains ; Models, Animal ; Pneumonia, Bacterial/drug therapy ; Pneumonia, Bacterial/immunology ; Pneumonia, Bacterial/microbiology ; Treatment Failure
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2005-02-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 80340-6
    ISSN 1755-3245 ; 0008-6363
    ISSN (online) 1755-3245
    ISSN 0008-6363
    DOI 10.1016/j.cardiores.2004.09.031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial.

    Friederich, Philip W / Henny, Christiaan P / Messelink, Embert J / Geerdink, Mark G / Keller, Tymen / Kurth, Karl-Heinz / Büller, Harry R / Levi, Marcel

    Lancet (London, England)

    2003  Volume 361, Issue 9353, Page(s) 201–205

    Abstract: Background: Recombinant activated factor VII (factor VIIa) has prohaemostatic effects in bleeding patients with coagulation abnormalities. We aimed to test the hypothesis that recombinant factor VIIa could reduce perioperative blood loss in patients ... ...

    Abstract Background: Recombinant activated factor VII (factor VIIa) has prohaemostatic effects in bleeding patients with coagulation abnormalities. We aimed to test the hypothesis that recombinant factor VIIa could reduce perioperative blood loss in patients with normal coagulation systems. Therefore, we assessed safety and efficacy of this drug in patients undergoing retropubic prostatectomy, which is often associated with major blood loss and need for transfusion.
    Methods: In a double-blind, randomised placebo-controlled trial, we recorded blood loss and transfusion requirements in 36 patients undergoing retropubic prostatectomy, who were randomised to receive an intravenous bolus of recombinant factor VIIa (20 microg/kg or 40 microg/kg) or placebo in the early operative phase.
    Findings: Median perioperative blood loss was 1235 mL (IQR 1025-1407) and 1089 mL (928-1320) in groups given recombinant factor VIIa 20 microg/kg and 40 microg/kg, respectively, compared with 2688 mL (1707-3565) in the placebo group (p=0.001). Seven of twelve placebo-treated patients were transfused, whereas no patients who received 40 microg/kg recombinant factor VIIa needed transfusion. The odds ratio for receiving any blood product in patients treated with recombinant factor VIIa compared with control patients was 0 (95% CI 0.00-0.33) No adverse events arose.
    Interpretation: An injection of recombinant factor VIIa can reduce perioperative blood loss and eliminate the need for transfusion in patients undergoing major surgery.
    MeSH term(s) Aged ; Blood Loss, Surgical/prevention & control ; Double-Blind Method ; Factor VII/therapeutic use ; Factor VIIa ; Humans ; Intraoperative Complications ; Male ; Middle Aged ; Prostatectomy/methods ; Recombinant Proteins/therapeutic use
    Chemical Substances Recombinant Proteins ; Factor VII (9001-25-6) ; recombinant FVIIa (AC71R787OV) ; Factor VIIa (EC 3.4.21.21)
    Language English
    Publishing date 2003-01-18
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0140-6736 ; 0023-7507
    ISSN (online) 1474-547X
    ISSN 0140-6736 ; 0023-7507
    DOI 10.1016/S0140-6736(03)12268-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Selective expansion of influenza A virus-specific T cells in symptomatic human carotid artery atherosclerotic plaques.

    Keller, Tymen T / van der Meer, Jelger J / Teeling, Peter / van der Sluijs, Koen / Idu, Mirza M / Rimmelzwaan, Guus F / Levi, Marcel / van der Wal, Allard C / de Boer, Onno J

    Stroke

    2008  Volume 39, Issue 1, Page(s) 174–179

    Abstract: Background and purpose: Evidence is accumulating that infection with influenza A virus contributes to atherothrombotic disease. Vaccination against influenza decreases the risk of atherosclerotic syndromes, indicating that inflammatory mechanisms may be ...

    Abstract Background and purpose: Evidence is accumulating that infection with influenza A virus contributes to atherothrombotic disease. Vaccination against influenza decreases the risk of atherosclerotic syndromes, indicating that inflammatory mechanisms may be involved. We tested the hypothesis that influenza A virus-specific T cells contribute to atherosclerotic plaque inflammation, which mediates the onset of plaque rupture.
    Methods: T-cell cultures were generated from atherosclerotic segments and peripheral blood of 30 patients with symptomatic carotid artery disease. The response of plaque and peripheral blood T cells to influenza A virus was analyzed and expressed as a stimulation index (SI). Selective outgrowth of intraplaque influenza A-specific T cells was calculated by the ratio of plaque T cell SI and peripheral blood T cell SI for each patient. Accordingly, the patients were categorized as high- (SI ratio >or=5), intermediate- (5 <SI ratio <or=2), and non- (SI ratio <2) responders. The presence of influenza A virus in the vessel fragments was evaluated by reverse transcription-polymerase chain reaction.<br />Results: High proliferative responses of plaque-derived T cells to influenza A virus were frequently observed. Among the 30 patients, 5 were categorized as high responders, 10 were intermediate responders, and 15 were nonresponders. Live influenza A virus could not be detected in the atherosclerotic plaques by polymerase chain reaction.
    Conclusions: Selective outgrowth of influenza A virus-specific T cells occurs within the microenvironment of human atherosclerotic plaques. Influenza virus-derived antigens or alternatively, mimicry antigens, appear to be potential candidates for triggering or sustaining plaque inflammation, which eventually leads to symptomatic plaque complications.
    MeSH term(s) Antigens, Viral/metabolism ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/pathology ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/pathology ; Carotid Artery Diseases/immunology ; Carotid Artery Diseases/pathology ; Carotid Stenosis/immunology ; Carotid Stenosis/pathology ; Cells, Cultured ; Endarterectomy, Carotid ; Humans ; Inflammation/immunology ; Inflammation/pathology ; Influenza A virus/immunology ; Influenza, Human/complications
    Chemical Substances Antigens, Viral
    Language English
    Publishing date 2008-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80381-9
    ISSN 1524-4628 ; 0039-2499 ; 0749-7954
    ISSN (online) 1524-4628
    ISSN 0039-2499 ; 0749-7954
    DOI 10.1161/STROKEAHA.107.491282
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Influenza infection and risk of acute pulmonary embolism.

    van Wissen, Matthijs / Keller, Tymen T / Ronkes, Brechje / Gerdes, Victor Ea / Zaaijer, Hans L / van Gorp, Eric Cm / Brandjes, Dees Pm / Levi, Marcel / Büller, Harry R

    Thrombosis journal

    2007  Volume 5, Page(s) 16

    Abstract: Background: Influenza infections have been associated with procoagulant changes. Whether influenza infections lead to an increased risk of pulmonary embolism remains to be established.: Methods: We conducted a nested case control study in a large ... ...

    Abstract Background: Influenza infections have been associated with procoagulant changes. Whether influenza infections lead to an increased risk of pulmonary embolism remains to be established.
    Methods: We conducted a nested case control study in a large cohort of patients with a clinical suspicion of having pulmonary embolism. Blood samples were collected to investigate the presence of influenza A and B by complement fixation assay (CFA). We compared case patients, in whom pulmonary embolism was proven (n = 102), to controls, in whom pulmonary embolism was excluded (n = 395). Furthermore, we compared symptoms of influenza-like illness in both patient groups 2 weeks prior to inclusion in the study, using the influenza-like illness (ILI) score, which is based on a questionnaire. We calculated the risk of pulmonary embolism associated with influenza infection.
    Results: The percentage of patients with influenza A was higher in the control group compared to the case group (4.3% versus 1.0%, respectively, odds ratio 0.22; 95% CI: 0.03-1.72). Influenza B was not detectable in any of the cases and was found in 3 of the 395 controls (0.8%). The ILI score was positive in 24% of the cases and 25% in the control persons (odds ratio 1.16, 95% CI: 0.67-2.01). We did not observe an association between the ILI score and proven influenza infection.
    Conclusion: In this clinical study, influenza infection was not associated with an increased risk of acute pulmonary embolism. The ILI score is non-specific in this clinical setting.
    Language English
    Publishing date 2007-10-16
    Publishing country England
    Document type Journal Article
    ISSN 1477-9560
    ISSN (online) 1477-9560
    DOI 10.1186/1477-9560-5-16
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women.

    Keller, Tymen T / van Leuven, Sander I / Meuwese, Marijn C / Wareham, Nicholas J / Luben, Robert / Stroes, Erik S / Hack, C Erik / Levi, Marcel / Khaw, Kay-Tee / Boekholdt, S Matthijs

    Arteriosclerosis, thrombosis, and vascular biology

    2006  Volume 26, Issue 10, Page(s) 2345–2350

    Abstract: Objective: To determine the association between serum levels of mannose-binding lectin (MBL) and the risk of future coronary artery disease (CAD) in apparently healthy men and women.: Methods and results: We performed a prospective case-control study ...

    Abstract Objective: To determine the association between serum levels of mannose-binding lectin (MBL) and the risk of future coronary artery disease (CAD) in apparently healthy men and women.
    Methods and results: We performed a prospective case-control study among apparently healthy men and women nested in the EPIC-Norfolk cohort. Baseline concentrations of MBL were measured in serum samples of 946 patients who experienced a myocardial infarction or died of CAD during follow-up, and 1799 matched controls who remained free of CAD. Among men, median MBL levels were 1.63 ng/mL (interquartile range [IQR]: 0.59 to 3.80) in cases and 1.20 ng/mL (IQR: 0.48 to 3.37) in controls. Among women, median MBL levels were 1.02 ng/mL (IQR: 0.43 to 2.95) in cases and 1.01 ng/mL (IQR: 0.43 to 2.94) in controls. After adjustment, the odds ratio in men for future CAD was 1.59 (95% confidence interval [CI]: 1.09 to 2.32; P for linearity=0.01) for those in the highest quartile compared with those in the lowest quartile. In women no such relation was observed.
    Conclusions: Elevated levels of MBL are associated with an increased risk of future CAD in apparently healthy men but not in women. The sex difference merits further exploration.
    MeSH term(s) Aged ; Case-Control Studies ; Coronary Artery Disease/etiology ; Female ; Humans ; Male ; Mannose-Binding Lectin/blood ; Middle Aged ; Prospective Studies ; Risk Assessment ; Risk Factors ; Sex Characteristics
    Chemical Substances Mannose-Binding Lectin
    Language English
    Publishing date 2006-08-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1221433-4
    ISSN 1524-4636 ; 1079-5642
    ISSN (online) 1524-4636
    ISSN 1079-5642
    DOI 10.1161/01.ATV.0000240517.69201.77
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top